Chapter 89 Scoring Systems for Comparison of Disease Severity in Intensive Care Unit Patients
Scores at ICU admission
2 Which scores are used for assessing the general severity of disease at ICU admission?
The three most frequently used systems are the:
3 Why were scores to assess general disease severity at ICU admission developed?
To assess performance of the ICU. The ICU patient is a medical or a surgical patient who has either acute failure of one major vital function or a high risk for development of such failure. Because the mortality rate of ICU populations is usually high and varies widely depending on patient admission policies, an objective assessment of the patients’ general disease severity is necessary to ensure that the mortality rate in an ICU is consistent with the overall severity of its patient population at admission. The ratio between observed and predicted mortality, called the standardized mortality ratio, is the simplest way to assess the performance of an ICU. It allows comparisons among mortality rates of various ICUs or the mortality rates documented in one ICU over time.
To assess the patient’s risk for death. The scores give an objective evaluation that helps the clinician confirm the severity of the patient’s illness. However, these scores cannot be used to make decisions about individual patients (e.g., withdrawal of support).
To compare or match populations in clinical studies. In randomized, controlled studies the scores have been used to confirm that the populations obtained by randomization had a similar disease severity at admission to the ICU. In case-control studies, the scores have been used to match the control to the case patients.
6 Which scores have been validated adequately?
The SAPS II is well validated. The score needs to be updated with more recent ICU populations.
The MPM II is well validated and has the advantage of being the only score available at ICU admission rather than at 24 hours after admission. This advantage is made possible because the score includes some therapeutic items (e.g., venous lines, drainage systems). The MPM II score also needs to be updated with more recent ICU populations.
The APACHE III is well validated and updated regularly, but its use is limited by the fact that clinicians must pay to know and use its equation for calculating death probability.
The APACHE IV and the MPM III are well calibrated, and they have a good discrimination; they were validated in a multicentered study of 11,300 ICU patients from California showing that APACHE IV had better discrimination and longer data extraction time than MPM III. MPM III was also validated in 55,459 patients from 103 ICUs, 25 of which did not participate in the original development.
The SAPS III is well validated and updated as it was published in 2005, that is, 12 years after the most recent among the other ones. Unlike the APACHE III, its construction details were diffused to the entire scientific community. It appears to be a good candidate for an international benchmark, and its use is free of charge.